Treatment of Symptomatic Calf Vein Thrombosis

Initial Anticoagulation Strategy

The American College of Chest Physicians recommends starting therapeutic anticoagulation immediately with either low molecular weight heparin (LMWH), unfractionated heparin, or fondaparinux, overlapped with warfarin from day 1, for patients with symptomatic calf vein thrombosis, including peroneal vein thrombosis 1, 2
Warfarin should be overlapped with parenteral anticoagulation for at least 2 days once therapeutic INR (2.0-3.0) is achieved, then parenteral therapy can be discontinued, as recommended by the Journal of the American Geriatrics Society 2
The target INR of 2.5 (range 2.0-3.0) is recommended for all treatment durations, as higher intensity anticoagulation provides no additional benefit and increases bleeding risk, according to the American College of Chest Physicians and the Journal of the American Geriatrics Society 1, 3

The American College of Chest Physicians recommends treating provoked calf vein thrombosis by surgery or major trauma for exactly 3 months and then discontinuing anticoagulation, with no extended therapy indicated regardless of bleeding risk 1, 4
For unprovoked calf vein thrombosis, treatment should be for at least 3 months, then reassess for extended therapy, with consideration of extended anticoagulation if low or moderate bleeding risk exists, as recommended by the American College of Chest Physicians 1, 5
If associated with active cancer, the American College of Chest Physicians recommends using LMWH preferentially over warfarin for long-term therapy and extended anticoagulation, even with moderate-to-high bleeding risk 1

The American College of Chest Physicians recommends against confusing symptomatic calf vein thrombosis with superficial vein thrombosis, which would only require prophylactic-dose anticoagulation, and notes that the peroneal vein is a deep vein requiring full therapeutic anticoagulation 6
IVC filter is NOT indicated unless absolute contraindication to anticoagulation exists, as filters in calf vein thrombosis carry complication rates without reducing PE incidence, according to the American College of Chest Physicians 1, 4

The American College of Chest Physicians recommends reassessing bleeding risk periodically (e.g., annually) if extended anticoagulation is chosen, to minimize the risk of bleeding complications 1, 5